Opinion

When the lab falls silent: The challenge of culture-negative urinary tract infections

Falah Hasan Obayes AL-Khikani*

Department of Medical Laboratory Technology, College of Medical Technology, The Islamic University, Najaf, Iraq
*E-mail: falahgh38@gmail.com

Culture-negative urinary tract infections (UTIs) present a significant diagnostic dilemma when patients exhibit clinical symptoms and pyuria despite negative standard urine cultures. This opinion categorizes the underlying causes into three distinct groups: established mechanisms (prior antibiotic use, biofilms, and fastidious organisms), emerging concepts (urinary microbiome and viable but nonculturable bacteria), and future directions (bacteriophages and epigenetic modifications). While advanced diagnostics like metagenomics offer promise, their clinical utility is still evolving. This article provides a structured overview of these mechanisms and discusses a practical diagnostic approach for clinicians, bridging current knowledge with future innovations to improve patient management.

UTIs present a persistent diagnostic paradox: a patient with classic symptoms and pyuria whose standard urine culture returns negative. This phenomenon, known as a culture-negative UTI, is a growing clinical challenge that leads to diagnostic uncertainty and delayed or inappropriate treatment. The traditional diagnostic algorithm, relying on a specific colony-forming unit threshold, is increasingly recognized as insufficient for capturing the full spectrum of urinary tract pathology.[1] This discrepancy stems from a complex interplay of host factors, microbial biology, and the limitations of conventional diagnostics. Factors such as prior antibiotic use, viable but nonculturable (VBNC) bacteria, and biofilms have long been implicated.[2,3] More recently, our understanding has expanded to include the urinary microbiome and fastidious organisms not detectable by standard methods.[4] This article aims to provide a structured analysis of this enigma by categorizing the mechanisms, evaluating emerging diagnostic tools, and proposing a practical framework for clinicians.

ESTABLISHED MECHANISMS FOR CULTURE-NEGATIVE URINARY TRACT INFECTIONS

Prior antibiotic exposure is a primary reason for false-negative cultures. Even a single dose can suppress bacterial growth *in vitro* below the detection threshold without eradicating the infection, despite persistent symptoms.[2] This highlights the importance of obtaining a detailed medication history. In addition, technical issues in sample collection, transportation, or processing can diminish bacterial viability and reduce culture positivity.

Standard urine culture protocols are optimized for common uropathogens like *Escherichia coli* but fail to support "fastidious" organisms with complex nutritional or atmospheric needs. Organisms such as *Gardnerella vaginalis* and *Ureaplasma urealyticum* have been implicated in UTI-like symptoms but are not detected by conventional methods.[1]

Biofilm-associated infections are a critical factor in recurrent and chronic UTIs. Bacteria encased within a self-produced matrix on surfaces such as the bladder wall or catheters exhibit reduced growth rates and profound antibiotic tolerance. Standard cultures primarily detect free-floating (planktonic) bacteria, and if the infection is locked within a biofilm, the number of shed bacteria may be too low to yield a positive culture, leading to a misleading negative result whereas the patient remains symptomatic.[3]

EMERGING CONCEPTS WITH GROWING EVIDENCE

Beyond established mechanisms, molecular evidence is reshaping our understanding. Under stress, such as antibiotic exposure, many bacteria can enter a dormant, VBNC state. In this state, bacteria remain alive and virulent but lose the ability to form colonies on standard media. Common uropathogens such as *Escherichia coli* and *Klebsiella pneumoniae* use this survival strategy, which explains why symptoms can persist despite a negative culture.[5]

Furthermore, the dogma of a sterile bladder has been overturned. The bladder hosts a diverse "urinary microbiome" (urobiome). Dysbiosis, or an imbalance in this community, may contribute to UTI symptoms even in the absence of a single dominant pathogen. Since metagenomic sequencing is required to characterize the urobiome, these complex community dynamics are invisible to standard culture methods, representing a major frontier in UTI research.[4]

FUTURE DIRECTIONS AND SPECULATIVE HYPOTHESES

Looking ahead, several new concepts are at the frontier of UTI research. The urinary tract is also home to a "virome," including bacteriophages – viruses that infect bacteria. It is hypothesized that in some cases, a high concentration of lytic bacteriophages could destroy uropathogens within the urine sample before or during laboratory processing, leading to a false-negative culture.[6] While this concept requires further validation, studying the dynamic interplay between bacteria and their phages could offer novel diagnostic and therapeutic insights.

Another area of research is bacterial adaptation through epigenetic modifications or metabolic shifts, which may temporarily "silence" genes required for growth on artificial media. Metabolomic profiling may 1 day identify unique metabolic "fingerprints" of these adapted bacteria. The urine matrix itself may also contain inhibitory substances,



Figure 1: Steps in diagnosis of culture-negative urinary tract infection. UTI: Urinary tract infection, EQUC: Enhanced quantitative urine culture, PCR: Polymerase chain reaction

such as antiseptics or high urea concentrations, that impede bacterial growth *in vitro*.[7] Host immune responses, including antimicrobial peptides, can further inhibit bacterial proliferation outside the body. In some cases, a low bacterial load, particularly in early or localized infections, may fall below the detection threshold of standard methods.[8]

CLINICAL IMPLICATIONS AND DIAGNOSTIC PATHWAY

Clinicians should maintain a high index of suspicion for culture-negative UTIs in patients with persistent symptoms, pyuria, and known risk factors such as recurrent infections or recent antibiotic use. Available but underutilized tools include enhanced quantitative urine culture (EQUC) for fastidious organisms and targeted molecular diagnostics that identify pathogen DNA directly from urine.

Future investigational tools hold greater promise. Metagenomic sequencing (mNGS) can provide a comprehensive view of the urobiome, although its use is limited by cost and complex data interpretation.[8] Metabolomics and biosensors aim to detect bacterial metabolic signatures, offering potential for rapid, point-of-care diagnosis.[9] AI-driven diagnostics may 1 day integrate vast datasets to predict the likelihood of a culture-negative UTI.[10] However, it is crucial to balance the search for occult pathogens with the risks of overdiagnosis and antibiotic overuse. A pragmatic approach involves first ruling out established causes and considering advanced diagnostics for patients with recurrent, debilitating symptoms where conventional methods have failed [Figure 1].

CONCLUSION

The challenge of the symptomatic, culture-negative UTI requires a paradigm shift away from a sole reliance on traditional culture. The discrepancy between clinical symptoms and laboratory results reflects complex biological realities, including prior antibiotic use, biofilms, and the presence of fastidious or nonculturable bacteria. While emerging concepts like the urinary microbiome offer new perspectives, their clinical application is still evolving. The path forward involves integrating a higher index of suspicion with the judicious use of advanced diagnostics, such as EQUC and targeted molecular tests, particularly for patients with recurrent or refractory symptoms. Bridging the gap between clinical presentation and diagnostic detection is key to improving patient outcomes and ensuring appropriate antimicrobial stewardship.

REFERENCES

1. Mancuso G, Midiri A, Gerace E, Marra M, Zummo S, Biondo C. Urinary tract infections: The current scenario and future prospects. Pathogens 2023;12:623.
2. Rosenthal VD, Memish ZA, Nicastri E, Leone S, Bearman G. Preventing catheter-associated urinary tract infections: A position paper of the international society for infectious diseases, 2024 update. Int J Infect Dis 2025;151:107304.
3. Dsouza FP, Dinesh S, Sharma S. Understanding the intricacies of microbial biofilm formation and its endurance in chronic infections: A key to advancing biofilm-targeted therapeutic strategies. Arch Microbiol 2024;206:85.
4. Wolfe AJ, Brubaker L. Urobiome updates: Advances in urinary microbiome research. Nat Rev Urol 2019;16:73-4.
5. AL-Khikani FH, Alhusayni AA, Jasim SH. Nitrofurantoin and Fosfomycin activity for uropathogenic *Escherichia coli* with extended-spectrum beta-lactamase. Med J DY Patil Univ 2024;17:S417-8.
6. Goh GS, Parvizi J. Diagnosis and treatment of culture-negative periprosthetic joint infection. J Arthroplasty 2022;37:1488-93.
7. Moreland RB, Choi BI, Geaman W, Gonzalez C, Hochstedler-Kramer BR, John J, *et al*. Beyond the usual suspects: Emerging uropathogens in the microbiome age. Front Urol 2023;3:121-9.
8. Xie R, Li X, Li G, Fu R. Diagnostic value of different urine tests for urinary tract infection: A systematic review and meta-analysis. Transl Androl Urol 2022;11:325-35.
9. Mach KE, Wong PK, Liao JC. Biosensor diagnosis of urinary tract infections: A path to better treatment? Trends Pharmacol Sci 2011;32:330-6.
10. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. Nat Med 2019;25:44-56.

Received: 11.12.2025, **Revised:** 28.01.2026,

Accepted: 29.01.2026, **Published:** 27.03.2026

Financial support and sponsorship: Nil.

Conflicts of interest: There are no conflicts of interest.

Access this article online	
Quick Response Code:	Website: www.indianjurol.com
	DOI: 10.4103/iju.iju_595_25

How to cite this article: AL-Khikani FH. When the lab falls silent: The challenge of culture-negative urinary tract infections. Indian J Urol 2026;42:96-8.